Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of …
Over the last 12 months, insiders at Centessa Pharmaceuticals plc have bought $0 and sold $8.26M worth of Centessa Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Centessa Pharmaceuticals plc have bought $75.13M and sold $3.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $92,568 was made by SAHA SAURABH (Chief Executive Officer) on 2022‑06‑24.
2024-11-13 | Sale | Chief Executive Officer | 32,023 0.0284% | $18.28 | $585,419 | -9.46% | ||
2024-10-25 | Sale | Chief Business Officer | 11,742 0.0103% | $15.38 | $180,628 | 0.00% | ||
2024-10-23 | Sale | Chief Executive Officer | 2,592 0.0023% | $15.32 | $39,697 | 0.00% | ||
2024-10-22 | Sale | Chief Executive Officer | 30,203 0.027% | $15.67 | $473,169 | 0.00% | ||
2024-10-21 | Sale | Chief Executive Officer | 22,205 0.0196% | $15.80 | $350,861 | +1.33% | ||
2024-09-25 | Sale | Chief Business Officer | 16,619 0.0148% | $15.69 | $260,724 | -0.12% | ||
2024-09-20 | Sale | Chief Executive Officer | 55,000 0.0484% | $16.53 | $908,985 | -3.56% | ||
2024-09-10 | Sale | Chief Executive Officer | 175,000 0.1752% | $16.52 | $2.89M | +9.67% | ||
2024-09-10 | Sale | Chief Business Officer | 30,000 0.0309% | $17.00 | $510,000 | +9.67% | ||
2024-09-09 | Sale | Chief Business Officer | 25,000 0.0222% | $15.00 | $375,000 | +7.10% | ||
2024-08-23 | Sale | Chief Executive Officer | 46,651 0.0395% | $12.30 | $573,905 | +23.35% | ||
2024-08-23 | Sale | Chief Business Officer | 17,802 0.015% | $12.29 | $218,792 | +23.35% | ||
2024-08-22 | Sale | Chief Executive Officer | 506 0.0004% | $12.23 | $6,188 | +29.75% | ||
2024-08-22 | Sale | Chief Business Officer | 12,198 0.0107% | $12.17 | $148,430 | +29.75% | ||
2024-08-21 | Sale | Chief Executive Officer | 3,674 0.0033% | $12.25 | $44,989 | +29.48% | ||
2024-08-20 | Sale | Chief Executive Officer | 4,169 0.0038% | $12.32 | $51,368 | +31.45% | ||
2024-03-25 | Sale | Chief People Officer | 51,160 0.0541% | $11.88 | $607,960 | -6.13% | ||
2024-02-01 | Sale | SVP Regulatory Affairs | 4,267 0.0043% | $8.10 | $34,574 | +34.89% | ||
2023-09-20 | Sale | SVP Regulatory Affairs | 37,484 0.0391% | $6.29 | $235,688 | +43.62% | ||
2023-06-01 | Sale | EVP & Chairman of Development | 6,500 0.0065% | $4.45 | $28,949 | +56.55% |
SAHA SAURABH | Chief Executive Officer | 630661 0.479% | $18.11 | 3 | 10 | <0.0001% |
Weinhoff Gregory M | Chief Business Officer | 183266 0.1392% | $18.11 | 1 | 8 | <0.0001% |
GAP (Bermuda) LTD | 10 percent owner | 9681818 7.3537% | $18.11 | 1 | 0 | <0.0001% |
De Rubertis Francesco | director | 3936970 2.9903% | $18.11 | 6 | 0 | <0.0001% |
Medicxi Ventures Management (Jersey) Ltd | 10 percent owner | 3936970 2.9903% | $18.11 | 6 | 0 | <0.0001% |
Medicxi Growth I Lp | $225.58M | 17.66 | 19.96M | 0% | +$0 | 50.22 | |
General Atlantic | $109.4M | 8.57 | 9.68M | 0% | +$0 | 2.84 | |
Ecor1 Capital Llc | $63.49M | 4.97 | 5.62M | 0% | +$0 | 0.45 | |
Vida Ventures Advisors Llc | $44.43M | 3.48 | 3.93M | 0% | +$0 | 24.68 | |
Perceptive Advisors | $34.84M | 2.73 | 3.08M | New | +$34.84M | 0.02 |